FTC Faces Uphill Battle In AndroGel Pay-For-Delay Suit

While the Federal Trade Commission won a court order requiring AbbVie to turn over documents in its AndroGel patent settlement the judge dismissed a big chunk of the agency’s complaint.

The Federal Trade Commission was dealt a set-back in its AndroGel pay-for-delay suit against AbbVie Inc. when the court tossed a big chunk of the complaint in May. But the agency is pressing forward and last week won a court order requiring AbbVie to turn over documents it claims are protected by attorney-client privilege.

FTC filed the complaint against AbbVie, AbbVie partner Besins Healthcare Inc. and Teva Pharmaceuticals USA Inc. last year. It...

More from Legal & IP

More from Pink Sheet